Evaluation of Skin Attributes Following Dietary Supplement Consumption

Skin Condition Clinical Trial

Official title:

A Randomized, Double Blinded, Placebo Controlled Clinical Study to Evaluate Skin Attributes Following Dietary Supplement Consumption

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03487965
• Other study ID #: CRL119515
• Status: Completed
• Phase: N/A
• First received: March 29, 2018
• Last updated: April 4, 2018
• Start date: April 28, 2016
• Est. completion date: June 28, 2017

Study information

• Verified date: April 2018
• Source: Access Business Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is to assess skin attributes of female subjects following 16 weeks of dietary supplement consumption.

Description:

This is a 16 week, randomized, double blind, placebo controlled study. Approximately 105 Caucasian and Asian (Korean, Japanese, or Chinese) female subjects will be enrolled. The following clinical assessments will be performed: (1)VISIA-CR™ digital photography; (2)AGE Reader SU measurements on the left cheek and left inner forearm; (3) Visual Analog Grading (VAS); (4) Corneometer measurements; and (5) Cutometer measurements. Subjects will return to the clinic at approximately 4 weeks, 8 weeks and 16 weeks from the baseline visit for similar measurements. A self-perception questionnaire will be administered at the conclusion of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 103
• Est. completion date: June 28, 2017
• Est. primary completion date: June 28, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 30 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject is a Caucasian or Asian (either Korean, Japanese, or Chinese) female between the ages of 30 and 65 years;

• Subject is overweight or moderately obese, with a BMI between 27 and 33;

• Subject is Caucasian and qualifies based on AGE Reader assessment that is at or greater than average for chronological age; OR is Asian and has an obtainable AGE Reader assessment on the left forearm. Screening AGE reader assessment will be done on the left inner forearm;

• Subject is willing to have fasting blood draws and urine collections at specified visits. At least nine hours fasting is required. Subject is allowed to drink water;

• Subject is willing to refrain from excessive sun exposure and/or the use of tanning beds;

• Subject is willing to use daily the provided facial SPF moisturizer and Purpose® cleansing bar;

• Subject is taking well established, stable doses of prescription and nonprescription medications not indicated to treat a thyroid condition or diabetes;

• Subject is in generally good health as determined by the medical history and blood panel results in the opinion of the Principal Investigator;

• Subject is dependable and able to follow directions as outlined in the protocol;

• Subject agrees to complete and sign a Photography Release Form, providing consent for the capture of facial digital images for use in relation to this clinical study;

• Subject has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164;

• Subject understands and is willing to sign an Informed Consent in conformance with 21 CFR Part 50: "Protection of Human Subjects."

Exclusion Criteria:

• Subject is pregnant, planning to become pregnant, or nursing;

• Subject is known to have, or at risk for, photosensitivity reactions (e.g. very sensitive to ultraviolet light);

• Subject has scars, tattoos, moles, age spots or rashes on the tested areas that the AGE Reader sensor and Cutometer® probe need to be placed;

• Subject takes prescription anticoagulants (this does not include a daily 81 mg dose of Aspirin);

• Subject has a history of any type of cancer and/or is currently undergoing treatment for any type of cancer;

• Subject has either a systolic blood pressure above 160 or a diastolic blood pressure above 100 at any time during the study;

• Subject has a thyroid condition;

• Subject is diabetic or taking any medication or herbal supplement to lower their blood glucose

Related Conditions & MeSH terms

• Skin Condition
• Skin Diseases

Intervention

Dietary Supplement:
• Low dose Polyphenol
botanical supplement with 25 mg polyphenol
• High dose Polyphenol
botanical supplement with 13 mg polyphenol
• Placebo Control
inert tablet made to mimic the experimental tablets

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Access Business Group	Clinical Research Laboratories

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Skin Autofluoresence	Change of accumulation of glycation as measured by validated autofluoresence measuring device (AGE Reader)	Change from baseline to 16 weeks, change from 8 weeks to 16 weeks
Secondary	Skin elasticity	Relationship between elasticity and skin glycation; elasticity will be measured by cutometer	Change from baseline to 16 weeks; change from 8 weeks to 16 weeks